卡培他滨单药治疗老年晚期胃癌临床研究

The Clinical Study of Capecitabine Regimen as First-Line Therapy for Patients with Advanced Gastric Cancer

目的观察卡培他滨作为一线药物治疗老年晚期胃癌的疗效及安全性。方法对36例具有可测量指标的老年晚期胃癌患者采用卡培他滨2 500 mg/(m2.d),分早晚2次服用,连服14 d,21 d为1周期,连用3周期为1个疗程,化疗后休息1个月评定疗效。结果36例中CR 1例、PR 11例、SD 13例、PD 11例,有效率33.33%,肿瘤控制率为(CR+PR+SD)为69.44%。主要毒副反应为厌食、恶心、呕吐、腹泻、手足综合征、皮肤色素沉着、白细胞减少、转氨酶升高等。毒副反应轻微,多为Ⅰ/Ⅱ级。结论卡培他滨作为一线药物治疗老年或体质差的晚期胃癌患者有较好疗效,毒副反应轻。

Objective To evaluate the objective response rate and toxicity of paelitaxel regimen as first-line therapy for old patients with advanced gastric cancer. Methods Thirty-six patients with advanced gastric cancer were administrated with oral eapeeitabine 2 500 mg/（ m2 · d） （ d1-14 ） in a 21-day cycle of therapy for 3 cycles. Results The thirty-six patients were assessable for efficacy and toxicity. One patient achieved a complete response and 11 patients had partial responses, with an overall response rate of 33.33%. The most common adverse effects were gastrointestinal response and myelosuppression. There was no chemotherapy-related death. Conclusions The eapeeitabine is effective and well tolerated as first-line therapy for old patients with advanced gastric cancer.